BridgeBio Pharma, Inc. research snapshot
BBIO AI stock analysis currently views BridgeBio as a commercial-stage genetic-disease company whose near-term economics are increasingly tied to Attruby while future value also depends on late-stage pipeline execution. At the July 11, 2026 cutoff, the latest public close was $90.17, verified market capitalization was about $17.68 billion, and cash, cash equivalents, and marketable securities were $940.2 million at March 31. Revenue growth is real, but net losses, substantial debt and royalty obligations, clinical and regulatory uncertainty, and an RSI of 86.79 make this a high-risk setup. This BBIO AI stock analysis uses scenarios instead of a certain price prediction and is for informational use, not investment advice.
Current price
$90.17 at the July 9, 2026 close
Market cap
$17.68 billion
AI score
58 / 100
Rating
Commercial-stage rare-disease company with strong Attruby growth and high pipeline, leverage, and valuation risk
Trend status
Above the 50-day and 200-day averages, but momentum was extended at the cutoff
Data cutoff (updated weekly)
July 11, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | BridgeBio discovers, develops, and commercializes medicines for genetic diseases. Customers and payers pay when an approved therapy demonstrates sufficient clinical value, access, and persistence. | Medium |
| Moat | The moat rests on patents, scientific know-how, clinical evidence, regulatory exclusivity, rare-disease expertise, and commercial execution. It must be earned and renewed by each program rather than assumed from the platform label. | Medium-low |
| Management | Management has funded a broad genetic-disease portfolio and recently authorized a $500 million repurchase program. The central test is allocating capital while converting Attruby demand into durable economics and advancing the pipeline efficiently. | Medium |
| Financial trend | FY2025 revenue was $502.08 million, including $362.37 million of Attruby product revenue. Q1 2026 revenue reached $194.52 million, but Q1 net loss attributable to common stockholders was $164.04 million. | High |
| Valuation | At $90.17, financial_rigor.py calculated negative trailing PE and FCF yield because BBIO remains loss-making. Conventional earnings multiples are not decision-useful, so the market value primarily reflects Attruby durability and pipeline expectations. | Medium |
| Technical trend | The July 9 snapshot put BBIO above its 50-day average of $69.36 and 200-day average of $68.99, but RSI of 86.79 indicated extended momentum that needs live-chart confirmation. | Medium |
| Risk level | Risk is high. Attruby uptake, pricing and reimbursement, competition, trial data, FDA decisions, cash burn, debt, deferred royalty obligations, dilution, and a sharp valuation reset can all change the thesis quickly. | High |
| AI confidence | Reported data are well supported, but AI cannot reliably forecast trial success, regulatory outcomes, payer behavior, future financing, or the market response to new evidence. | High data confidence |
| Investment certainty | Investment certainty is low to medium because current commercial momentum is observable while the long-term earnings path, pipeline value, and capital burden remain uncertain. | Low-medium |
BBIO AI stock forecast
The BBIO AI stock forecast is scenario-based, not a point target. The mandatory three-scenario EPS calculation produces non-economic negative values because current EPS is negative, so it is not used as a valuation target. The ranges below frame commercial and pipeline outcomes around the July 9, 2026 close.
$100 to $125
More likely if Attruby demand and persistence remain strong, international uptake expands, BBP-418 and encaleret progress through review and launch, infigratinib data continue to support differentiation, and spending or financing needs stay controlled.
$70 to $100
More likely if Attruby growth continues but investors retain a large discount for losses, debt, royalty obligations, pipeline timing, reimbursement, competition, and the uncertainty of future program economics.
$40 to $65
More likely if Attruby growth slows, access or competition pressures revenue, a material trial or regulatory event disappoints, cash needs increase, financing dilutes holders, or the market re-rates high-multiple biopharma assets lower.
BBIO AI technical analysis
BBIO AI technical analysis uses the latest public snapshot available at the July 11, 2026 cutoff: $90.17 at the July 9 close, 50-day moving average of $69.36, 200-day moving average of $68.99, RSI of 86.79, beta of 0.95, and 20-day average volume of 4.82 million shares. This static page does not fetch request-time data. Confirm every level in a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $90.17 | Public closing quote on July 9, 2026. Refresh the quote before any decision. |
| Near support | $69.36 | Reported 50-day moving average at the cutoff. A sustained loss would weaken the intermediate trend. |
| Deeper support | $68.99 | Reported 200-day moving average at the cutoff. Moving averages change daily and require a live check. |
| Near resistance | $90 to $95 | The July 9 closing area is a reference zone after a sharp move, not a chart-derived price target. |
| Moving averages | 50-day $69.36; 200-day $68.99 | The cutoff quote was above both averages, supporting the trend while it remains live-chart dependent. |
| Momentum | RSI 86.79 | Momentum was extended. High RSI can persist, but it increases the need for position sizing and confirmation. |
| Volume | 20-day average 4.82 million shares | Use above-average volume and relevant company news to validate a breakout or reversal. |
| Volatility | 5-year beta 0.95 | Event-driven biopharma moves can exceed historical beta, especially around data, FDA, reimbursement, and earnings updates. |
| Invalidation | Decisive close below the live 50-day average | For a trend-following framework, a confirmed break below the live 50-day average near $69.36 is an invalidation condition, not a personal sell instruction. |
BBIO AI trading strategy
The BBIO AI trading strategy is a rules-based research framework, not personalized advice. It combines live price confirmation with Attruby prescriptions and persistence, revenue mix, gross margin, R&D and SG&A, cash, debt, royalty obligations, share count, FDA calendars, trial data, and competitor developments.
Wait for BBIO to hold above the live 50-day average and for any advance beyond the current $90 to $95 reference area to have volume confirmation and an unchanged commercial or pipeline thesis. Check trial, FDA, and earnings dates before relying on a chart pattern.
Define risk before entry. A failed breakout or decisive close below the live 50-day average near $69.36 can invalidate this setup.
If BBIO pulls back toward the moving averages without a negative commercial, clinical, regulatory, or financing update, wait for stabilization and compare the move with Attruby sales, cash, debt, royalty obligations, and program timelines.
Do not average down because a share price fell. The setup fails if support breaks alongside weaker demand, adverse data, delayed approval, or a higher funding requirement.
Track Attruby net product revenue, patient and prescriber trends, BEYONTTRA royalties, gross margin, operating expenses, cash and marketable securities, debt and deferred royalty obligations, buyback activity, diluted shares, FDA decisions, trial readouts, payer access, and competitor treatment data.
Refresh all scenarios after material earnings, clinical data, an FDA decision, a financing or royalty transaction, a program discontinuation, or a large price gap. Avoid stale technical levels around binary events.
Investment research summary
BridgeBio applies genetic science to discover, develop, and commercialize medicines for patients with significant unmet need. Its economic value depends on generating evidence, securing approval and access, and turning approved therapies into persistent product revenue.
Relevant protections are patents, scientific know-how, clinical data, regulatory exclusivity, rare-disease focus, specialist relationships, and commercial execution. These advantages matter only if each medicine shows a durable clinical and economic case relative to alternatives.
The thesis can fail if Attruby growth slows, payer access narrows, a competing therapy gains share, clinical data disappoint, safety or manufacturing issues emerge, regulators delay or reject applications, cash needs rise, or debt and royalty obligations constrain flexibility.
The management test is capital allocation under uncertainty: protect commercial execution, fund the highest-value programs, control overhead, manage obligations, and use repurchases only when they do not compromise the balance sheet or development runway.
Genetic medicine and rare-disease treatment can create substantial value when evidence, diagnosis, reimbursement, and specialist adoption align. The path is discontinuous and shaped by trial design, regulation, payer access, manufacturing, competition, and patient persistence.
The verified $17.68 billion market capitalization reflects current Attruby momentum plus expectations for pipeline assets. With negative trailing EPS and free cash flow, a margin of safety cannot be read from PE or FCF multiples. It requires conservative assumptions about demand, program success, spending, financing, and obligations.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| BBIO price and market capitalization | $90.17 close on July 9, 2026; $17.68 billion market capitalization; 196.04 million shares outstanding. financial_rigor.py verified price times shares with a 0.02% difference from reported market cap. | StockAnalysis statistics, verified with financial_rigor.py | July 11, 2026 |
| FY2025 revenue | $502.08 million, including $362.37 million of Attruby net product revenue. SEC and StockAnalysis values matched within 0.01%. | BridgeBio 2025 Form 10-K, cross-checked with StockAnalysis | July 11, 2026 |
| FY2025 net loss attributable to common stockholders | Negative $724.93 million. SEC and StockAnalysis values matched within 0.01%. | BridgeBio 2025 Form 10-K, cross-checked with StockAnalysis | July 11, 2026 |
| Q1 2026 revenue and net loss | $194.52 million total revenue, including $180.60 million of Attruby net product revenue; net loss attributable to common stockholders was $164.04 million. | BridgeBio Q1 2026 results and Form 8-K | July 11, 2026 |
| Cash and marketable securities | $940.19 million at March 31, 2026. FY2025 cash and short-term investments were $587.48 million and matched SEC and StockAnalysis within 0.01%. | BridgeBio Q1 2026 results, 2025 Form 10-K, and StockAnalysis | July 11, 2026 |
| Capital obligations | At March 31, 2026, 2033, 2031, 2029, and 2027 notes totaled about $2.47 billion net and deferred royalty obligations were $871.19 million. | BridgeBio Q1 2026 results and Form 8-K | July 11, 2026 |
| Technical snapshot | 50-day average $69.36; 200-day average $68.99; RSI 86.79; 20-day average volume 4.82 million; beta 0.95. | StockAnalysis statistics | July 11, 2026 |
| Pipeline and capital-allocation update | Q1 update described positive BBP-418 and infigratinib milestones; the board authorized a repurchase program of up to $500 million on May 6, 2026. | BridgeBio Q1 2026 results and Form 8-K | July 11, 2026 |
This BBIO page is an informational research tool, not investment advice, a recommendation, or a guarantee of performance. Forecast ranges are scenarios based on available dated data and assumptions that can be wrong. Verify live market data and primary filings before making an investment decision.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
